Results 71 to 80 of about 2,138,197 (387)

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Cancer Cell International, 2020
Background In recent years, the B cell receptor (BCR) signaling pathway has become a “hot point” because it plays a critical role in B-cell proliferation and function. Bruton’s tyrosine kinase (BTK) is overexpressed in many subtypes of B-cell lymphoma as
Chao Xue, Xin Wang, Lingyan Zhang, Qingyuan Qu, Qian Zhang, Yujie Jiang   +5 more
doaj   +1 more source

Metagenomic deep sequencing of aqueous fluid detects intraocular lymphomas. [PDF]

, 2017
IntroductionCurrently, the detection of pathogens or mutations associated with intraocular lymphomas heavily relies on prespecified, directed PCRs. With metagenomic deep sequencing (MDS), an unbiased high-throughput sequencing approach, all pathogens as ...
Acharya, Nisha, Bloomer, Michele, DeRisi, Joseph L, Doan, Thuy, Gonzales, John, Shantha, Jessica G, Wilson, Michael R   +6 more
core   +1 more source

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

The Combined Inhibition of SREBP and mTORC1 Signaling Synergistically Inhibits B‐Cell Lymphoma

Cancer Medicine
Background The sterol regulatory element‐binding protein (SREBP) pathway is essential for maintaining sterol homeostasis during B cell activation and germinal center B cell proliferation.
Zhenhan Zhu, Wenxia Jiang, Jiehao Zhou, Alexander Robert Maldeney, Jingru Liang, Jing Yang, Wei Luo   +6 more
doaj   +1 more source

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead [PDF]

, 2015
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in
Auperin, Anne, Brugi\ue8res, Laurence, Burkhardt, Birgit, Cairo, Mitchell S, Damm Welk, Christine, Gross, Thomas G, Horibe, Keizo, Klapper, Wolfram, Lamant, Laurence, Le Deley, Marie C\ue9cile, Macintyre, Elizabeth, Minard Colin, V\ue9ronique, Mussolin, Lara, Patte, Catherine, Perkins, Sherrie L, Pillon, Marta, Poirel, H\ue9l\ue8ne A, Raphael, Martine, Reiter, Alfred, Rosolen, Angelo, Sandlund, John T, Williams, Denise, Woessmann, Wilhelm, Zimmerman, Martin   +23 more
core   +1 more source

Developmental Disorders in Children Recently Diagnosed With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurocognitive deficits in adult survivors of childhood cancer are well established, but less is known about developmental disorders (DD) arising shortly after cancer diagnosis. Using 2016–2019 linked Ohio cancer registry and Medicaid data, we compared DD among 324 children with cancer and 606,913 cancer‐free controls.
Jamie Shoag, Long Vu, Ritika Miryala, Jeffrey M. Albert, Molly McVoy, Siran M. Koroukian   +5 more
wiley   +1 more source

EBV Positive Diffuse Large B Cell Lymphoma with Negative Pan-B Cell Markers, Case Report, and Literature Review

Case Reports in Hematology
Most B cell lymphomas are positive for one or more B cell markers including CD19, CD20, CD79a, or PAX5. However, rare cases of mature B cell lymphoma not expressing any B cell markers have been characterized and recognized as distinct diagnostic entities
Janna Shold, Lea Jukic, Daniel Farrell, Wei Cui, Da Zhang   +4 more
doaj   +1 more source

CAR T Cell Toxicity: Current Management and Future Directions

HemaSphere, 2019
. By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in the treatment of patients up to 25 years of age with B-cell acute ...
Lucrecia Yáñez, Miriam Sánchez-Escamilla, Miguel-Angel Perales   +2 more
doaj   +1 more source

Combined detection of lymphocyte clonality and MALT1 translocations in bronchoalveolar lavage fluid for diagnosing pulmonary lymphomas

Scientific Reports, 2021
Diagnosis of pulmonary lymphoma using small tissue samples is difficult and often requires surgical procedures; thus, a less invasive sampling method is desirable.
Takashi Kido, Hiroshi Ishimoto, Hiroshi Ishii, Kanako Hara, Mutsumi Ozasa, Hiroki Kawabata, Toshinori Kawanami, Yu Suzuki, Hiroki Yoshikawa, Atsuko Hara, Noriho Sakamoto, Nobuhiro Matsumoto, Chiharu Yoshii, Junya Fukuoka, Masaki Fujita, Masamitsu Nakazato, Junichi Kadota, Hiroshi Mukae, Kazuhiro Yatera   +18 more
doaj   +1 more source

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]

, 2011
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V, Fanale MA, Hasenclever D, Katrina Farrell, Mike Leach, Orlandi E, Pamela Mckay, Savage KJ, Stein H   +8 more
core   +1 more source